ChromaDex Corp. (NASDAQ: CDXC) announced today that results from a human clinical study of NIAGEN®, a cutting-edge form of vitamin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE